Article
Oncology
Elham Sajjadi, Konstantinos Venetis, Roberto Piciotti, Donatella Gambini, Concetta Blundo, Letterio Runza, Stefano Ferrero, Elena Guerini-Rocco, Nicola Fusco
Summary: The loss of PTEN is associated with tumorigenesis, tumor progression, and therapy resistance in breast cancer patients. Patients with PTEN-low tumors showed significantly enriched hormone receptor negativity and HER2 negativity compared to those with PTEN-retained tumors. The combined analysis of PTEN, HER2, and hormone receptor status provides relevant information for a more precise risk assessment of patients with breast cancer.
Review
Biochemistry & Molecular Biology
Alexandra Moisand, Mathilde Madery, Thomas Boyer, Charlotte Domblides, Celine Blaye, Nicolas Larmonier
Summary: Breast cancers are a heterogeneous group of diseases with varying responses to current therapies. Hormone receptor-positive breast cancers can benefit from endocrine therapies, but metastatic disease remains a challenge. Immunotherapies have had limited success in breast cancer, only benefiting patients with hormone receptor-negative tumors. Current research focuses on the role of hormone receptor signaling in the sensitivity of breast cancer cells to anti-tumor immune responses and the potential of hormone therapy agents to enhance immune-based interventions.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Dongxu Ma, Qing Yang, Ke Yin, Peng Shi, Xiao Chen, Tianyi Dong, Xingchen Shang, Xingsong Tian
Summary: This study compared the prognosis of triple-positive breast cancer and HER2-positive breast cancer, and found that the 5-year disease-free survival and overall survival rates were significantly better in the triple-positive group than in the HER2-positive group.
FRONTIERS IN ONCOLOGY
(2023)
Review
Oncology
Mattia Garutti, Gaia Griguolo, Andrea Botticelli, Giulia Buzzatti, Carmine De Angelis, Lorenzo Gerratana, Chiara Molinelli, Vincenzo Adamo, Giampaolo Bianchini, Laura Biganzoli, Giuseppe Curigliano, Michelino De Laurentiis, Alessandra Fabi, Antonio Frassoldati, Alessandra Gennari, Caterina Marchio, Francesco Perrone, Giuseppe Viale, Claudio Zamagni, Alberto Zambelli, Lucia Del Mastro, Sabino De Placido, Valentina Guarneri, Paolo Marchetti, Fabio Puglisi
Summary: Breast cancer is a leading cause of cancer-related morbidity and mortality in women worldwide, and estimating the risk of relapse for individual cases remains challenging. The IRIDE working group reviewed literature evidence to identify the relevant features predicting relapse in hormone receptor-positive/HER2-negative early breast cancer, aiming to provide guidance for clinicians in managing these cases effectively.
Article
Biochemistry & Molecular Biology
Diogo J. Silva, Goncalo Miranda, Teresina Amaro, Matilde Salgado, Alexandra Mesquita
Summary: Tumor budding (TB) is a dynamic process associated with the epithelial-mesenchymal transition and has been proven to be a significant prognostic biomarker for colorectal cancer. This study aimed to investigate the clinical applicability and prognostic value of TB in patients with early breast cancer (EBC). The results showed a significant association between high TB score and aggressive clinicopathological features, as well as poor prognosis. The findings suggest that TB could serve as a valuable prognostic biomarker for EBC.
Article
Medicine, General & Internal
Solange Moraes Sanches, Alexcia Camila Braun, Vinicius Fernando Calsavara, Paula Nicole Vieira Pinto Barbosa, Ludmilla Thome Domingos Chinen
Summary: This study aimed to compare the expression of ER, PR, and HER2 in primary tumors, CTCs, and metastases in breast cancer patients, and evaluate TGF-beta RI expression in CTCs as a prognostic factor. The results suggest that using CTC detection methods in non-triple-negative cases may impact patient prognosis.
Article
Pharmacology & Pharmacy
Jie Chen, Jin Zhu, Shuai-Jun Xu, Jun Zhou, Xiao-Fei Ding, Yong Liang, Guang Chen, Hong-Sheng Lu
Summary: TM4SF1 is downregulated in HR(+)HER2(-) breast cancer, and its overexpression suppresses cell proliferation in this cancer subtype.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Immunology
Sofia Batalha, Catarina Monteiro Gomes, Catarina Brito
Summary: This study presents a unique human 3D model for studying the immune effects of anti-HER2 biologicals, which can be used to test novel therapy regimens and improve anti-tumor immune function.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Federica Miglietta, Gaia Griguolo, Michele Bottosso, Tommaso Giarratano, Marcello Lo Mele, Matteo Fassan, Matilde Cacciatore, Elisa Genovesi, Debora De Bartolo, Grazia Vernaci, Ottavia Amato, Francesca Porra, PierFranco Conte, Valentina Guarneri, Maria Vittoria Dieci
Summary: The expression of HER2-low-positive shows high instability from primary breast cancer to residual disease after neoadjuvant treatment. HER2-low-positive expression in residual disease may guide personalized adjuvant treatment for high-risk patients in clinical trials.
Article
Oncology
Saranya Chumsri, Zhuo Li, Daniel J. Serie, Nadine Norton, Afshin Mashadi-Hossein, Kathleen Tenner, Heather Ann Brauer, Sarah Warren, Patrick Danaher, Gerardo Colon-Otero, Ann H. Partridge, Lisa A. Carey, Florentine Hilbers, Veerle Van Dooren, Eileen Holmes, Serena Di Cosimo, Olena Werner, Jens Bodo Huober, Amylou C. Dueck, Christos Sotiriou, Cristina Saura, Alvaro Moreno-Aspitia, Keith L. Knutson, Edith A. Perez, E. Aubrey Thompson
Summary: This study identified a novel adaptive immune signature (AIS) that is significantly associated with improved outcomes in breast cancer patients treated with trastuzumab. AIS-low patients have poor outcomes despite receiving trastuzumab, but benefit from an addition of lapatinib.
Review
Medicine, General & Internal
Cassandra L. Moyer, Powel H. Brown
Summary: Advancements in research have led to a decline in breast cancer mortality over the past thirty years, but the incidence of breast cancer continues to rise. This calls for more effective prevention strategies, including targeted chemo preventive agents. Recent efforts have focused on exploring the role of nuclear receptors in breast cancer development and progression. Drugs targeting nuclear receptors, such as retinoic acid receptor, retinoid X receptor, and vitamin D receptor, have shown potential for preventing both hormone receptor-positive and hormone receptor-negative breast cancer.
FRONTIERS IN MEDICINE
(2023)
Article
Oncology
Mengdi Chen, Weilin Chen, Deyue Liu, Weiguo Chen, Kunwei Shen, Jiayi Wu, Li Zhu
Summary: HER2-low breast cancer and HER2-zero breast cancer have similar survival outcomes in HR+ patients, with HER2-low patients having a higher proportion of tumors with high ER expression. RS and its proliferation module may have less predictive value in HER2-low patients.
Article
Medicine, General & Internal
Paul Mozarowski, Bhubendra Rasaiah, Melissa Reed, Alexis Lewis, Natalie Walde, Ioannis A. Voutsadakis
Summary: Tumor budding is common in breast cancer patients receiving neo-adjuvant therapy, but it was not found to be associated with tumor characteristics or pathological responses to treatment in this study. Further investigation is needed to determine the potential prognostic value of tumor budding in specific subgroups of breast cancer patients.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Hyo-Jae Lee, Jong Eun Lee, Won Gi Jeong, So Yeon Ki, Min Ho Park, Ji Shin Lee, Yoo Kyeong Nah, Hyo Soon Lim
Summary: This study aimed to explore the associations between clinicopathologic and MRI features with tumor-infiltrating lymphocyte (TIL) levels in HER2-positive breast cancer patients. Of the patients, 83.5% had TIL levels below 10%. High TIL levels were positively associated with histologic grade, tumor cellularity, frequency of associated ductal carcinoma in situ, and peritumoral edema on T2-weighted images. Subanalysis based on hormone receptor status showed that histologic grade was an independent predictor of high TIL level in the HR-positive/HER2-positive group, while tumor cellularity, peritumoral edema, and low ADC were independent predictors in the HR-negative/HER2-positive group.
AMERICAN JOURNAL OF ROENTGENOLOGY
(2022)
Article
Oncology
G. Griguolo, G. Serna, T. Pascual, R. Fasani, X. Guardia, N. Chic, L. Pare, S. Pernas, M. Munoz, M. Oliveira, M. Vidal, A. Llombart-Cussac, J. Cortes, P. Galvan, B. Bermejo, N. Martinez, R. Lopez, S. Morales, I Garau, L. Manso, J. Alarcon, E. Martinez, P. Villagrasa, A. Prat, P. Nuciforo
Summary: In HER2+ breast cancer, changes in the density of immune cells in the tumor microenvironment after anti-HER2 treatment, particularly those interacting spatially with tumor cells, are associated with treatment response. Furthermore, patients achieving pathologic complete response show a consistent decrease in stromal tumor-infiltrating lymphocytes (sTILs) post-surgery, while residual tumors often remain inflamed, suggesting a progressive loss of T cell function. Understanding the implications of the resulting immunosuppressive microenvironment is crucial for developing effective strategies for early-stage HER2+ breast cancer therapy.
NPJ PRECISION ONCOLOGY
(2021)
Article
Pathology
Julia Unternaehrer, Rainer Grobholz, Andrew Janowczyk, Inti Zlobec
JOURNAL OF CLINICAL PATHOLOGY
(2020)
Article
Pathology
Christina Neppl, Inti Zlobec, Ralph A. Schmid, Sabina Berezowska
Article
Biology
Caroline Contat, Pierre-Benoit Ancey, Nadine Zangger, Silvia Sabatino, Justine Pascual, Stephane Escrig, Louise Jensen, Christine Goepfert, Bernard Lanz, Mario Lepore, Rolf Gruetter, Anouk Rossier, Sabina Berezowska, Christina Neppl, Inti Zlobec, Stephanie Clerc-Rosset, Graham William Knott, Jeffrey C. Rathmell, E. Dale Abel, Anders Meibom, Etienne Meylan
Editorial Material
Medicine, General & Internal
Alessandro Lugli, Inti Zlobec
Editorial Material
Medicine, General & Internal
Behzad Bozorgtabar, Dwarikanath Mahapatra, Inti Zlobec, Tilman T. Rau, Jean-Philippe Thiran
FRONTIERS IN MEDICINE
(2020)
Article
Oncology
Bernhard Mlecnik, Carlo Bifulco, Gabriela Bindea, Florence Marliot, Alessandro Lugli, J. Jack Lee, Inti Zlobec, Tilman T. Rau, Martin D. Berger, Iris D. Nagtegaal, Elisa Vink-Borger, Arndt Hartmann, Carol Geppert, Julie Kolwelter, Susanne Merkel, Robert Gruetzmann, Marc Van den Eynde, Anne Jouret-Mourin, Alex Kartheuser, Daniel Leonard, Christophe Remue, Julia Y. Wang, Prashant Bavi, Michael H. A. Roehrl, Pamela S. Ohashi, Linh T. Nguyen, SeongJun Han, Heather L. MacGregor, Sara Hafezi-Bakhtiari, Bradly G. Wouters, Giuseppe V. Masucci, Emilia K. Andersson, Eva Zavadova, Michal Vocka, Jan Spacek, Lubos Petruzelka, Bohuslav Konopasek, Pavel Dundr, Helena Skalova, Kristyna Nemejcova, Gerardo Botti, Fabiana Tatangelo, Paolo Delrio, Gennaro Ciliberto, Michele Maio, Luigi Laghi, Fabio Grizzi, Tessa Fredriksen, Benedicte Buttard, Lucie Lafontaine, Daniela Bruni, Anastasia Lanzi, Carine El Sissy, Nacilla Haicheur, Amos Kirilovsky, Anne Berger, Christine Lagorce, Christopher Paustian, Carmen Ballesteros-Merino, Jeroen Dijkstra, Carlijn van de Water, Shannon van Lent-van Vliet, Nikki Knijn, Ana-Maria Musina, Dragos-Viorel Scripcariu, Boryana Popivanova, Mingli Xu, Tomonobu Fujita, Shoichi Hazama, Nobuaki Suzuki, Hiroaki Nagano, Kiyotaka Okuno, Toshihiko Torigoe, Noriyuki Sato, Tomohisa Furuhata, Ichiro Takemasa, Kyogo Itoh, Prabhu S. Patel, Hemangini H. Vora, Birva Shah, Jayendrakumar B. Patel, Kruti N. Rajvik, Shashank J. Pandya, Shilin N. Shukla, Yili Wang, Guanjun Zhang, Yutaka Kawakami, Francesco M. Marincola, Paolo A. Ascierto, Bernard A. Fox, Franck Pages, Jerome Galon
JOURNAL OF CLINICAL ONCOLOGY
(2020)
Article
Pathology
Eva Karamitopoulou, Irene Esposito, Inti Zlobec, Andrea Cacciato Insilla, Martin Wartenberg, David F. Schaeffer, Steve Kalloger, Stefano La Rosa, Christine Sempoux, Irene Ramos Centeno, Philipp Lohneis
Summary: Tumor budding has been identified as an independent prognostic factor in pancreatic ductal adenocarcinoma (PDAC) and its assessment methods showed moderate agreement levels between pathologists in a multicenter interobserver study. The pancytokeratin 10HPF method demonstrated acceptable levels of agreement and is recommended for tumor budding assessment in PDAC resection specimens. Implementing machine learning applications should be considered to improve interobserver agreement levels.
Article
Pathology
Tariq Sami Haddad, Alessandro Lugli, Susan Aherne, Valeria Barresi, Benoit Terris, John-Melle Bokhorst, Scarlet Fiona Brockmoeller, Miriam Cuatrecasas, Femke Simmer, Hala El-Zimaity, Jean-Francois Flejou, David Gibbons, Gieri Cathomas, Richard Kirsch, Tine Plato Kuhlmann, Cord Langner, Maurice B. Loughrey, Robert Riddell, Ari Ristimaki, Sanjay Kakar, Kieran Sheahan, Darren Treanor, Jeroen van der Laak, Michael Vieth, Inti Zlobec, Iris D. Nagtegaal
Summary: An international group of experts reached consensus on a standardized method for tumor budding assessment and reporting, which has been validated and included in international colorectal cancer pathology and clinical guidelines.
Article
Oncology
Palanivel Kandasamy, Inti Zlobec, Damian T. Nydegger, Jonai Pujol-Gimenez, Rajesh Bhardwaj, Senji Shirasawa, Toshiyuki Tsunoda, Matthias A. Hediger
Summary: Oncogenic KRAS mutations in colorectal cancer cells upregulate specific amino acid transporters (AATs) resulting in increased uptake of amino acids such as glutamine and leucine. The activation of mTOR and enhanced cell proliferation in KRAS mutant CRC cells is mediated through YAP1 transcriptional coactivator and the upregulation of AATs.
MOLECULAR ONCOLOGY
(2021)
Article
Pathology
Inti Zlobec, Melanie Baechli, Francesca Galuppini, Martin D. Berger, Heather E. Dawson, Iris D. Nagtegaal, Alessandro Lugli
Summary: The study investigated the potential clinical relevance of a new category of zero tumor buds in colorectal cancer, which was found to provide important information on tumor behavior.
Article
Medicine, General & Internal
Simone Benhamou, Evelyne Fournier, Giacomo Puppa, Thomas McKee, Frederic Ris, Laura Rubbia-Brandt, Valeria Viassolo, Thomas Zilli, Inti Zlobec, Pierre Olivier Chappuis, Elisabetta Rapiti
Summary: This study established a large cohort of colorectal cancer (CRC) patients and their relatives to investigate the impact of family history and tumor biomarkers on patient outcomes. The cohort includes 5499 patients and provides detailed clinical and molecular data. Future plans involve further research and correlation analysis with the latest follow-up data.
Article
Pathology
Magdalena Skoworonska, Annika Blank, Irene Centeno, Caroline Hammer, Aurel Perren, Inti Zlobec, Tilman T. Rau
Summary: The standardized preanalytical code (SPREC) is a precise format for aggregating warm ischemia (WIT), cold ischemia (CIT), and fixation times (FIT). Through empirical research, the Tissue Bank Bern has developed a fully informative SPREC code and identified its dual role as a sample characteristic and a traceable process parameter. The study also reveals specific differences in WIT, CIT, and FIT values in various organs, as well as the potential to optimize the SPREC fixation and adapt its categories based on real-life data.
JOURNAL OF PATHOLOGY CLINICAL RESEARCH
(2023)
Article
Biochemistry & Molecular Biology
Oxana (Sachenkova) Lundstrom, Max Adriaan Verbiest, Feifei Xia, Helyaneh Ziaei Jam, Inti Zlobec, Maria Anisimova, Melissa Gymrek
Summary: Short tandem repeats (STRs), consisting of repeated one to six nucleotide motifs, have been shown to influence various traits in humans. However, the study of STRs has been limited due to technical challenges. Recent advancements in genome-wide analysis tools have enabled large-scale analysis of STR variations in populations.
JOURNAL OF MOLECULAR BIOLOGY
(2023)
Article
Pathology
Ana Leni Frei, Raphael Oberson, Elias Baumann, Aurel Perren, Rainer Grobholz, Alessandro Lugli, Heather Dawson, Christian Abbet, Ibai Lertxundi, Stefan Reinhard, Aart Mookhoek, Johann Feichtinger, Rossella Sarro, Gallus Gadient, Corina Dommann-Scherrer, Jessica Barizzi, Sabina Berezowska, Katharina Glatz, Susanne Dertinger, Yara Banz, Rene Schoenegg, Laura Rubbia-Brandt, Achim Fleischmann, Guenter Saile, Pierre Mainil-Varlet, Ruggero Biral, Luca Giudici, Alex Soltermann, Audrey Baur Chaubert, Sylvia Stadlmann, Joachim Diebold, Kristof Egervaril, Charles Beniere, Francesca Saro, Andrew Janowczyk, Inti Zlobec
Summary: Estimating tumor cell fraction (TCF) is a common clinical task with high variability among pathologists. This study evaluated the impact of using a tumor cell fraction computer-aided diagnostic (TCFCAD) tool to support pathologists' evaluation. The results showed that with the assistance of TCFCAD, interobserver variability decreased and estimates were closer to the ground truth. Pathologists also reported increased confidence in their assessments when aided by the TCFCAD tool.
Correction
Biochemistry & Molecular Biology
Christian M. Schurch, Salil S. Bhate, Graham L. Barlow, Darci J. Phillips, Luca Noti, Inti Zlobec, Pauline Chu, Sarah Black, Janos Demeter, David R. McIlwain, Shigemi Kinoshita, Nikolay Samusik, Yury Goltsev, Garry P. Nolan
Article
Pathology
Xiaobo Zhang, Chen Wang, Danhua Shen
Summary: This study investigated the Clinicopathological features and FH mutation in FH-dUL. FH-dUL is rare and the combination of predictive Clinicopathological evaluation, FH and 2SC IHC test, and molecular test were helpful for the screening of FH-dUL or even HLRCC.
PATHOLOGY RESEARCH AND PRACTICE
(2024)
Review
Pathology
Gaurav Dubey, Mithilesh Singh, Himmat Singh, Mohit Agarwal, Shailendra Singh Chandel, Anurag Mishra, Ravindra Pal Singh, Neelima Kukreti
Summary: SnoRNAs play a crucial role in autoimmune diseases, influencing gene expression, immune cell development, and immune regulation. They have the potential to be biomarkers or therapeutic targets for disease management. However, further research is needed to elucidate their precise molecular mechanisms.
PATHOLOGY RESEARCH AND PRACTICE
(2024)
Article
Pathology
P. Suhaj, D. Do, T. Olejar, R. Pichova, O. Lang, R. Matej
Summary: Pancreatic polypeptide cell hyperplasia (PPY-H) is a multiplication of neuroendocrine cells producing pancreatic polypeptide (PPY). The development and role of PPY-H still need to be further elucidated. This study analyzed 12 cases of PPY-H accompanying pancreatic neuroendocrine neoplasias (NEN) and found that gastrointestinal symptoms may be more related to PPY-H rather than NEN hormonal production. Strong SSTR2 expression in PPY-H suggests the potential utility of radiotracers in clinical diagnostics, but further studies are needed.
PATHOLOGY RESEARCH AND PRACTICE
(2024)
Article
Pathology
Ruyun Zhang, Xiaofei Liao, Bin Zhang, Xiaohong Huang, Guanjie Qin, Xiangyun Kong, Yuan Xie, Yunyan Mo, Jinxuan Dai, Chunqiao Gan, Zan Luo, Jingyan Lu, Wei Jiang
Summary: This study found that patients with high COV+TIL score had worse prognosis in nasopharyngeal carcinoma.
PATHOLOGY RESEARCH AND PRACTICE
(2024)
Review
Pathology
Waleed Hassan Almalki
Summary: Understanding the molecular pathways behind cardiovascular illnesses is crucial. Recent studies have revealed the role of Xist RNA in cardiovascular diseases, including epigenetic changes, gene expression, cellular identity, and sex chromosomal inactivation. Dysregulation of Xist RNA expression is associated with conditions such as atherosclerosis, hypertrophy, and cardiac fibrosis.
PATHOLOGY RESEARCH AND PRACTICE
(2024)
Article
Pathology
Yanxin Dong, Boshi Fan, Mingyang Li, Jiale Zhang, Shun Xie, Shouyin Dia, Qingge Jia, Taiqian Gong
Summary: Tescalcin (TESC) is upregulated in esophageal squamous carcinoma (ESCC) and is associated with poor prognosis, tumor infiltration, staging, and lymph node metastasis. TESC promotes proliferation, invasion, migration, and epithelial-mesenchymal transition (EMT) progression in ESCC, as well as activates the AKT pathway. TESC may serve as a prognostic factor and provide a new therapeutic strategy for ESCC.
PATHOLOGY RESEARCH AND PRACTICE
(2024)
Article
Pathology
Ozge Sukruoglu Erdogan, Demet Akdeniz Odemis, Zubeyde Yalniz Kayim, Orkun Gurbuz, Seref Bugra Tuncer, Seda Kilic, Betul Celik, Samuray Tuncer, Sema Buyukkapu Bay, Rejin Kebudi, Hulya Yazici
Summary: This study found that methylation of the RB1 gene promoter does not influence the hereditary transmission of familial retinoblastoma.
PATHOLOGY RESEARCH AND PRACTICE
(2024)
Review
Pathology
Syam Mohan, Mohammed Ageeli Hakami, Hamad Ghaleb Dailah, Asaad Khalid, Asim Najmi, Khalid Zoghebi, Maryam A. Halawi, Thaifallah Munahi Alotaibi
Summary: Cancer is a complex disease caused by multiple factors, and miR-155 plays a significant role as a regulator of the NF-kappa B signaling pathway, contributing to cancer development and progression.
PATHOLOGY RESEARCH AND PRACTICE
(2024)